Do Antithymocyte Globulin-Free Acute Rejection Therapies Increase the Risk of Polyoma Nephropathy in Renal Transplant Recipients?

Basit Öğe Kaydı
dc.contributor.authorGünay E.
dc.contributor.authorZeytinoğlu A.
dc.contributor.authorŞen S.
dc.contributor.authorYılmaz M.
dc.contributor.authorAtay G.
dc.contributor.authorAşcı G.
dc.contributor.authorSezer T.O.
dc.contributor.authorTöz H.
dc.date.accessioned2019-10-26T21:12:18Z
dc.date.available2019-10-26T21:12:18Z
dc.date.issued2019
dc.departmentEge Üniversitesien_US
dc.description.abstractIntroduction: BK virus nephropathy is a serious complication that can lead to allograft kidney loss. Excessive immunosuppression increases the risk. We aimed to evaluate whether there is an increased risk of BK viremia and nephropathy in patients who underwent high-dose immunosuppression because of the development of acute rejection in the early period after kidney transplantation. Methods: This retrospective cohort study was performed between April 2015 and March 2016. Twenty-nine patients who had biopsy-proven acute rejection in the first 3 months were evaluated for BK viremia and nephropathy. Thirty patients who had transplantations at the same period were the control group. Plasma BK-DNA values were examined at 1, 2, 3, 6, 9, and 12 months after the rejection treatment and at 3, 6, 9, and 12 months in the control group. Presence of polyoma nephropathy was examined with surveillance biopsies at the 6 and 12 months. Results: Acute rejection treatment was started on the 12th day after transplantation (2–37 days). Seventeen cellular rejections and 12 humoral rejections were reported by biopsy. Two of the 12 humoral rejections were suspicious. Only pulse steroid (PS)(n = 18); PS, plasmapheresis, and intravenous immunoglobulin (n = 8); PS and intravenous immunoglobulin (n = 2); and PS and plasmapheresis (n = 1)treatments were performed. In 21 patients in the rejection group and 25 patients in the control group, BK-DNA was not positive at all. Two patients had graft loss at 11 and 36 months in the rejection group. Graft losses were secondary to rejection. Conclusions: Treatment with antithymocyte globulin-free regimens after acute rejection episodes did not lead to an increase in BK viremia. © 2019 Elsevier Inc.en_US
dc.identifier.doi10.1016/j.transproceed.2019.01.109en_US
dc.identifier.endpage1114en_US
dc.identifier.issn0041-1345
dc.identifier.issue4en_US
dc.identifier.pmid31101182en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage1112en_US
dc.identifier.urihttps://doi.org/10.1016/j.transproceed.2019.01.109
dc.identifier.urihttps://hdl.handle.net/11454/15665
dc.identifier.volume51en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevier USAen_US
dc.relation.ispartofTransplantation Proceedingsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleDo Antithymocyte Globulin-Free Acute Rejection Therapies Increase the Risk of Polyoma Nephropathy in Renal Transplant Recipients?en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu